| Fonds | 2026/Q1 | 2025/Q4 | 2025/Q3 | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Investment ($) | QoQ ($) | QoQ (%) | Investment ($) | QoQ ($) | QoQ (%) | Investment ($) | QoQ ($) | QoQ (%) | |
| 530.804.575 $ | +152.012.285 $ | +239,5 % | 268.484.698 $ | -231.740.979 $ | +45,3 % | 554.838.318 $ | +405.770.302 $ | +3.464,0 % | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 17.919.849 $ | -257.265.327 $ | -93,5 % | 275.185.176 $ | +270.550.842 $ | +5.838,0 % | |||
| GROUP ONE TRADING LLC | 105.152.376 $ | +102.868.338 $ | +4.503,8 % | ||||||
| RA CAPITAL MANAGEMENT, L.P. | 96.425.164 $ | +25.727.790 $ | +36,4 % | 70.697.374 $ | -25.880.331 $ | -26,8 % | 96.577.705 $ | +32.351.122 $ | +50,4 % |
| TCG Crossover Management, LLC | 96.499.052 $ | ||||||||
| FCPM III SERVICES B.V. | 73.453.595 $ | +26.138.605 $ | +55,2 % | 47.314.990 $ | +28.818.929 $ | +155,8 % | 18.496.061 $ | ||
| Venrock Adviser, LLC | 54.264.267 $ | +28.839.808 $ | +113,4 % | 25.424.459 $ | +1.066.115 $ | +4,4 % | 24.358.344 $ | ||
| Frazier Life Sciences Management, L.P. | 45.383.872 $ | +12.109.150 $ | +36,4 % | 33.274.722 $ | |||||
| Shay Capital LLC | 35.068.656 $ | ||||||||
| Caligan Partners LP | 34.343.177 $ | +24.380.205 $ | +244,7 % | ||||||
| FMR LLC | 27.467.713 $ | -5.574.591 $ | -16,9 % | 33.042.304 $ | +21.519.635 $ | +186,8 % | |||
| Paradigm Biocapital Advisors LP | 31.220.000 $ | +8.330.000 $ | +36,4 % | 22.890.000 $ | |||||
| GREAT POINT PARTNERS LLC | 31.220.000 $ | +13.299.000 $ | +74,2 % | 17.921.000 $ | |||||
| MARSHALL WACE, LLP | 20.574.444 $ | ||||||||
| STATE STREET CORP | 19.953.291 $ | +18.762.318 $ | +1.575,4 % | ||||||
| 530.804.575 $ | +152.012.285 $ | +239,5 % | 268.484.698 $ | -231.740.979 $ | +45,3 % | 554.838.318 $ | +405.770.302 $ | +3.464,0 % | |